生物技术进展 ›› 2026, Vol. 16 ›› Issue (2): 327-337.DOI: 10.19586/j.2095-2341.2025.0189
• 进展评述 • 上一篇
收稿日期:2025-12-24
接受日期:2026-01-29
出版日期:2026-03-25
发布日期:2026-04-27
通讯作者:
秦伟
作者简介:杨茜E-mail: coffeeyanyang@sohu.com;
基金资助:Received:2025-12-24
Accepted:2026-01-29
Online:2026-03-25
Published:2026-04-27
Contact:
Wei QIN
摘要:
慢性终末期肾病(end-stage renal disease, ESRD)作为现代肾脏病学面临的重大挑战,其病程进展与程序性细胞死亡(programmed cell death, PCD)密切相关,尤其是细胞焦亡和铁死亡发挥核心调控作用。这些PCD过程不仅受遗传和病理信号调控,还显著依赖机体营养状态与代谢供能水平。尽管围绕“营养-PCD-ESRD”的关联研究日益增多,但相关证据分散且机制认识尚未统一。基于此,系统回顾了ESRD及维持性血液透析(maintenance hemodialysis, MHD)患者中细胞焦亡与铁死亡的分子机制,明确了细胞焦亡通过“启动-放大-扩展”3阶段通路、铁死亡经“铁超载-抗氧化失衡-脂质过氧化放大”核心轴线,共同推动肾脏不可逆损伤。重点梳理了锌、维生素D、ω-3多不饱和脂肪酸、硒、维生素E、左卡尼汀及膳食纤维等营养素,通过调控上述PCD关键节点发挥的干预效应,证实营养干预可通过抑制炎性小体激活、修复抗氧化防御、调节铁代谢等多途径延缓疾病进展。同时指出当前精准营养治疗面临患者异质性高、证据强度不足、单一干预局限等挑战,提出未来需建立PCD 特征导向的精准分型体系、发展多靶点协同干预策略及配套技术支撑的研究方向以期为ESRD/MHD 患者的营养干预提供机制依据与转化思路,为基础研究与临床策略提供了参考。
中图分类号:
杨茜, 秦伟. 终末期肾病中细胞焦亡与铁死亡的机制及营养干预研究进展[J]. 生物技术进展, 2026, 16(2): 327-337.
Qian YANG, Wei QIN. Advances on Mechanisms of Pyroptosis and Ferroptosis in End-stage Renal Disease and Nutritional Interventions[J]. Current Biotechnology, 2026, 16(2): 327-337.
图1 ESRD/MHD患者细胞焦亡与铁死亡的关键病理通路及其营养干预靶点示意图
Fig. 1 Schematic diagram of key pathological pathways of pyroptosis and ferroptosis and nutritional intervention targets in ESRD/MHD patients
| [1] | LEVEY A S, ECKARDT K U, DORMAN N M, et al.. Nomenclature for kidney function and disease: executive summary and glossary from a kidney disease: improving Global Outcomes (KDIGO) Consensus Conference[J]. Transpl. Int., 2020, 33(9): 999-1009. |
| [2] | KATO S, CHMIELEWSKI M, HONDA H, et al.. Aspects of immune dysfunction in end-stage renal disease[J]. Clin. J. Am. Soc. Nephrol., 2008, 3(5): 1526-1533. |
| [3] | CHEN T, SUN X, TSUEI S, et al.. Care for end-stage kidney disease in China: progress, challenges, and recommendations[J/OL]. Lancet Reg. Health West. Pac., 2025, 54: 101268[2025-11-25]. . |
| [4] | CARRERO J J, STENVINKEL P, CUPPARI L, et al.. Etiology of the protein-energy wasting syndrome in chronic kidney disease: a consensus statement from the International Society of Renal Nutrition and Metabolism (ISRNM)[J]. J. Ren. Nutr., 2013, 23(2): 77-90. |
| [5] | LIU Y, LEI H, ZHANG W, et al.. Pyroptosis in renal inflammation and fibrosis: current knowledge and clinical significance[J/OL]. Cell Death Dis., 2023, 14(7): 472[2025-11-25]. . |
| [6] | LI X, GAO L, LI X, et al.. Autophagy, pyroptosis and ferroptosis are rising stars in the pathogenesis of diabetic nephropathy[J]. Diabetes Metab. Syndr. Obes., 2024, 17: 1289-1299. |
| [7] | KRAMER H. Diet and chronic kidney disease[J]. Adv. Nutr., 2019, 10(S4): 367-379. |
| [8] | RAPA S F, DI IORIO B R, CAMPIGLIA P, et al.. Inflammation and oxidative stress in chronic kidney disease-potential therapeutic role of minerals, vitamins and plant-derived metabolites[J/OL]. Int. J. Mol. Sci., 2019, 21(1): 263[2025-11-25]. . |
| [9] | CHEN J, LI X, GE C, et al.. The multifaceted role of ferroptosis in liver disease[J]. Cell Death Differ., 2022, 29(3): 467-480. |
| [10] | SANTOS J C, BOUCHER D, SCHNEIDER L K, et al.. Human GBP1 binds LPS to initiate assembly of a caspase-4 activating platform on cytosolic bacteria[J/OL]. Nat. Commun., 2020, 11(1): 3276[2025-11-25]. . |
| [11] | 赵艺玮,高甜璐,张佳辉,等.线粒体质量控制失衡导致糖尿病肾病肾间质纤维化的研究进展[J].生物技术进展,2024,14(5):825-831. |
| ZHAO Y W, GAO T L, ZHANG J H, et al.. Research progress on the imbalance of mitochondrial quality control leading to renal interstitial fibrosis in diabetic kidney disease[J]. Curr. Biotechnol., 2024, 14(5): 825-831. | |
| [12] | SCHRODER K, TSCHOPP J. The inflammasomes[J]. Cell, 2010, 140(6): 821-832. |
| [13] | YANG S, LI X, YANG F, et al.. Gut microbiota-dependent marker TMAO in promoting cardiovascular disease: inflammation mechanism, clinical prognostic, and potential as a therapeutic target[J/OL]. Front. Pharmacol., 2019, 10: 1360[2025-11-25]. . |
| [14] | 杨文领,何莲,李育梅,等.维持性血液透析患者血氧化三甲胺与心力衰竭的相关性及其影响因素[J].中华肾脏病杂志,2021,37(2):121-129. |
| YANG W L, HE L, LI Y M, et al.. Correlation analysis of blood trimethylamine N-oxide level with heart failure and its influencing factors in patients undergoing maintenance hemodialysis[J]. Chin. J. Nephrol., 2021, 37(2): 121-129. | |
| [15] | FANG L, SHEN J, XIAO N, et al.. TMAO activates the NLRP3 inflammasome, disrupts gut-kidney interaction, and promotes intestinal inflammation[J/OL]. Int. J. Mol. Sci., 2025, 26(15): 7441[2025-11-25]. . |
| [16] | BARNETT K C, LI S, LIANG K, et al.. A 360° view of the inflammasome: mechanisms of activation, cell death, and diseases[J]. Cell, 2023, 186(11): 2288-2312. |
| [17] | 徐雁,邹建洲,刘中华,等.维持性血液透析(MHD)患者外周血单个核细胞NF-κB活性与心血管疾病(CVD)相关[J].复旦学报(医学版),2012,39(4):353-359. |
| XU Y, ZOU J Z, LIU Z H, et al.. The relationship between NF-κB activity of peripheral blood mononuclear cell and cardiovascular disease (CVD) in patients of maintenance hemodialysis (MHD)[J]. Fudan Univ. J. Med. Sci., 2012, 39(4): 353-359. | |
| [18] | GUTIERREZ K D, DAVIS M A, DANIELS B P, et al.. MLKL activation triggers NLRP3-mediated processing and release of IL-1β independently of gasdermin-D[J]. J. Immunol., 2017, 198(5): 2156-2164. |
| [19] | CONOS S A, CHEN K W, DE NARDO D, et al.. Active MLKL triggers the NLRP3 inflammasome in a cell-intrinsic manner[J]. Proc. Natl. Acad. Sci. USA, 2017, 114(6):961-969. |
| [20] | HE Y, HARA H, NÚÑEZ G. Mechanism and regulation of NLRP3 inflammasome activation[J]. Trends Biochem. Sci., 2016, 41(12): 1012-1021. |
| [21] | KAYAGAKI N, STOWE I B, LEE B L, et al.. Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling[J]. Nature, 2015, 526(7575): 666-671. |
| [22] | BROZ P, DIXIT V M. Inflammasomes: mechanism of assembly, regulation and signalling[J]. Nat. Rev. Immunol., 2016, 16(7): 407-420. |
| [23] | MARCH D S, GRAHAM-BROWN M P M, STOVER C M, et al.. Intestinal barrier disturbances in haemodialysis patients: mechanisms, consequences, and therapeutic options[J/OL]. Biomed Res. Int., 2017: 5765417[2025-11-25]. . |
| [24] | SHI X, SUN Q, HOU Y, et al.. Recognition and maturation of IL-18 by caspase-4 noncanonical inflammasome[J]. Nature, 2023, 624(7991): 442-450. |
| [25] | SHI J, ZHAO Y, WANG K, et al.. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death[J]. Nature, 2015, 526(7575): 660-665. |
| [26] | LIU X, XIA S, ZHANG Z, et al.. Channelling inflammation: gasdermins in physiology and disease[J]. Nat. Rev. Drug Discov., 2021, 20(5): 384-405. |
| [27] | BAKER M L, CANTLEY L G. Adding insult to injury: the spectrum of tubulointerstitial responses in acute kidney injury[J/OL]. J. Clin. Invest., 2025, 135(6): e188358[2025-11-25].. |
| [28] | JIANG W J, XU C T, DU C L, et al.. Tubular epithelial cell-to-macrophage communication forms a negative feedback loop via extracellular vesicle transfer to promote renal inflammation and apoptosis in diabetic nephropathy[J]. Theranostics, 2022, 12(1): 324-339. |
| [29] | SHAO Y, DENG S, TANG W, et al.. Molecular mechanism of GSDMD mediated glomerular endothelial cells pyroptosis: an implying in the progression of diabetic nephropathy[J/OL]. Int. Immunopharmacol., 2023, 122: 110632[2025-11-25]. . |
| [30] | GANGEMI S, MALLAMACE A, MINCIULLO P L, et al.. Involvement of interleukin-18 in patients on maintenance haemodialysis[J]. Am. J. Nephrol., 2002, 22(5-6): 417-421. |
| [31] | KAMBARA H, LIU F, ZHANG X, et al.. Gasdermin D exerts anti-inflammatory effects by promoting neutrophil death[J]. Cell Rep., 2018, 22(11): 2924-2936. |
| [32] | JIANG X, STOCKWELL B R, CONRAD M. Ferroptosis: mechanisms, biology and role in disease[J]. Nat. Rev. Mol. Cell Biol., 2021, 22(4): 266-282. |
| [33] | 金童,陈铖.铁死亡与肾脏疾病相关性的研究进展[J].生物技术进展,2022,12(1):68-74. |
| JIN T, CHEN C. Research progress on the correlation between ferroptosis and kidney diisease[J]. Curr. Biotechnol., 2022, 12(1): 68-74. | |
| [34] | WEISS G, GANZ T, GOODNOUGH L T. Anemia of inflammation[J]. Blood, 2019, 133(1): 40-50. |
| [35] | GANZ T, NEMETH E. Hepcidin and iron homeostasis[J]. Biochim. Biophys. Acta, 2012, 1823(9): 1434-1443. |
| [36] | ZHONG M, WANG Y, MIN J, et al.. Iron metabolism and ferroptosis in human health and disease[J/OL]. BMC Biol., 2025, 23(1): 263[2025-11-25]. . |
| [37] | GAO M, MONIAN P, PAN Q, et al.. Ferroptosis is an autophagic cell death process[J]. Cell Res., 2016, 26(9): 1021-1032. |
| [38] | DIXON S J, LEMBERG K M, LAMPRECHT M R, et al.. Ferroptosis: an iron-dependent form of nonapoptotic cell death[J]. Cell, 2012, 149(5): 1060-1072. |
| [39] | WANG W, CHEN J, ZHAN L, et al.. Iron and ferroptosis in kidney disease: molecular and metabolic mechanisms[J/OL]. Front. Immunol., 2025, 16: 1531577[2025-11-25]. . |
| [40] | YANG W S, SRIRAMARATNAM R, WELSCH M E, et al.. Regulation of ferroptotic cancer cell death by GPX4[J]. Cell, 2014, 156(1-2): 317-331. |
| [41] | SATO H, SHIIYA A, KIMATA M, et al.. Redox imbalance in cystine/glutamate transporter-deficient mice[J]. J. Biol. Chem., 2005, 280(45): 37423-37429. |
| [42] | ROSS E A, KOO L C, MOBERLY J B. Low whole blood and erythrocyte levels of glutathione in hemodialysis and peritoneal dialysis patients[J]. Am. J. Kidney Dis., 1997, 30(4): 489-494. |
| [43] | AL-BADRY S H, IBRAHIM N G, ALMASHHADANI H A, et al.. The role of oxidative stress in patients with chronic kidney disease[J]. Wiad. Lek., 2023, 76(5 pt 1): 951-955. |
| [44] | MAIORINO M, AUMANN K D, BRIGELIUS-FLOHÉ R, et al.. Probing the presumed catalytic triad of a selenium-containing peroxidase by mutational analysis[J]. Z. Ernahrungswiss., 1998, 37(): 118-121. |
| [45] | FU S, ZHANG L, MA F, et al.. Effects of selenium on chronic kidney disease: a mendelian randomization study[J/OL]. Nutrients, 2022, 14(21): 4458[2025-11-25]. . |
| [46] | ZACHARA B A, ADAMOWICZ A, TRAFIKOWSKA U, et al.. Selenium and glutathione levels, and glutathione peroxidase activities in blood components of uremic patients on hemodialysis supplemented with selenium and treated with erythropoietin[J]. J. Trace Elem. Med. Biol., 2001, 15(4): 201-208. |
| [47] | DWORKIN B, WESELEY S, ROSENTHAL W S, et al.. Diminished blood selenium levels in renal failure patients on dialysis: correlations with nutritional status[J]. Am. J. Med. Sci., 1987, 293(1): 6-12. |
| [48] | EL-FAR M A, BAKR M A, FARAHAT S E, et al.. Glutathione peroxidase activity in patients with renal disorders[J]. Clin. Exp. Nephrol., 2005, 9(2): 127-131. |
| [49] | BERSUKER K, HENDRICKS J M, LI Z, et al.. The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis[J]. Nature, 2019, 575(7784): 688-692. |
| [50] | LV Y, LIANG C, SUN Q, et al.. Structural insights into FSP1 catalysis and ferroptosis inhibition[J/OL]. Nat. Commun., 2023, 14(1):5933[2025-11-25]. . |
| [51] | NAKAMURA T, MISHIMA E, YAMADA N, et al.. Integrated chemical and genetic screens unveil FSP1 mechanisms of ferroptosis regulation[J]. Nat. Struct. Mol. Biol., 2023, 30(11): 1806-1815. |
| [52] | KRAFT V A N, BEZJIAN C T, PFEIFFER S, et al.. GTP cyclohydrolase 1/tetrahydrobiopterin counteract ferroptosis through lipid remodeling[J]. ACS Cent. Sci., 2020, 6(1): 41-53. |
| [53] | DAI Y, CHEN Y, MO D, et al.. Inhibition of ACSL4 ameliorates tubular ferroptotic cell death and protects against fibrotic kidney disease[J/OL]. Commun. Biol., 2023, 6(1): 907[2025-11-25].. |
| [54] | SHEN R, YU X, SHI C, et al.. ACSL4 predicts rapid kidney function decline in patients with diabetic kidney disease[J/OL]. Front. Endocrinol., 2025, 16: 1499555[2025-11-25]. . |
| [55] | DESSÌ M, NOCE A, BERTUCCI P, et al.. Plasma and erythrocyte membrane phospholipids and fatty acids in Italian general population and hemodialysis patients[J/OL]. Lipids Health Dis., 2014, 13: 54[2025-11-25]. . |
| [56] | 赖玮婧,黄蓉双,王波,等.肾脏病中铁死亡的病理生理机制和药物疗法研究进展[J].中华肾脏病杂志,2024,40(5):411-417. |
| LAI W J, HUANG R S, WANG B, et al.. Researches progress on the pathogenesis mechanism of ferroptosis and pharmacotherapy in kidney diseases[J]. Chin. J. Nephrol., 2024, 40(5): 411-417. | |
| [57] | 后瑞禛,龚凤英. SCD1的表达调节及其调节糖脂代谢机制的研究进展[J].国际内分泌代谢杂志,2024,44(2):114-118. |
| HOU R Z, GONG F Y. Research progress on the expression and regulation of SCD1 and its relationship with glucose and lipid metabolism[J]. Int. J. Endocrinol. Metab., 2024, 44(2): 114-118. | |
| [58] | NAKATANI S, MORIOKA T, MORIOKA F, et al.. Zinc deficiency in chronic kidney disease and hemodialysis: insights from basic research to clinical implications[J/OL]. Nutrients, 2025, 17(13): 2191[2025-11-25]. . |
| [59] | ELGENIDY A, AMIN M A, AWAD A K, et al.. Serum zinc levels in chronic kidney disease patients, hemodialysis patients, and healthy controls: systematic review and meta-analysis[J]. J. Ren. Nutr., 2023, 33(1): 103-115. |
| [60] | GONG X, GU W, FU S, et al.. Zinc homeostasis regulates caspase activity and inflammasome activation[J/OL]. PLoS Pathog., 2024, 20(12): e1012805[2025-11-25]. . |
| [61] | WANG L J, WANG M Q, HU R, et al.. Effect of zinc supplementation on maintenance hemodialysis patients: a systematic review and meta-analysis of 15 randomized controlled trials[J/OL]. Biomed Res. Int., 20172017:1024769[2025-11-25]. . |
| [62] | 罗改香,韩蕾,权金星.维生素D调控细胞焦亡的作用机制研究进展[J].广西医学,2023,45(24):3046-3050. |
| LUO G X, HAN L, QUAN J X. Mechanism of vitamin D for the regulation of pyroptosis: a research progress[J]. Guangxi Med. J., 2023, 45(24): 3046-3050. | |
| [63] | JIANG S, ZHANG H, LI X, et al.. Vitamin D/VDR attenuate cisplatin-induced AKI by down-regulating NLRP3/Caspase-1/GSDMD pyroptosis pathway[J/OL]. J. Steroid Biochem. Mol. Biol., 2021, 206: 105789[2025-11-25]. . |
| [64] | YAN Y, JIANG W, SPINETTI T, et al.. Omega-3 fatty acids prevent inflammation and metabolic disorder through inhibition of NLRP3 inflammasome activation[J]. Immunity, 2013, 38(6): 1154-1163. |
| [65] | TAYYEBI-KHOSROSHAHI H, HOUSHYAR J, TABRIZI A, et al.. Effect of omega-3 fatty acid on oxidative stress in patients on hemodialysis[J]. Iran. J. Kidney Dis., 2010,4(4):322-326. |
| [66] | TAYYEBI-KHOSROSHAHI H, HOUSHYAR J, DEHGAN-HESARI R, et al.. Effect of treatment with omega-3 fatty acids on C-reactive protein and tumor necrosis factor-Alfa in hemodialysis patients[J]. Saudi J. Kidney Dis. Transpl., 2012, 23(3): 500-506. |
| [67] | LOK C E, FARKOUH M, HEMMELGARN B R, et al.. Fish-oil supplementation and cardiovascular events in patients receiving hemodialysis[J]. N. Engl. J. Med., 2026, 394(2): 128-137. |
| [68] | LEE C T, LIAO S C, HSU K T, et al.. Low dose desferrioxamine can improve erythropoiesis in iron-overload hemodialysis patients without side effects[J]. Ren. Fail., 1999, 21(6): 665-673. |
| [69] | DE CÁSSIA S O L R, THEODORO J M V, SILVA B PDA, et al.. Synbiotic meal decreases uremic toxins in hemodialysis individuals: a placebo-controlled trial[J]. Food Res. Int., 2019, 116: 241-248. |
| [70] | BOGYE G, TOMPOS G, ALFTHAN G. Selenium depletion in hemodialysis patients treated with polysulfone membranes[J]. Nephron, 2000, 84(2): 119-123. |
| [71] | 张夏明,徐刚,鄢巨振,等.血硒对维持性血液透析患者左心室结构与功能的影响[J].临床肾脏病杂志,2020,20(1):19-24. |
| ZHANG X M, XU G, YAN J Z, et al.. Effect of blood selenium on left ventricular structure and function in maintenance hemodialysis patients[J]. J. Clin. Nephrol., 2020, 20(1): 19-24. | |
| [72] | BARTFAY W J, BARTFAY E. Decreasing effects of iron toxicosis on selenium and glutathione peroxidase activity[J]. West. J. Nurs. Res., 2002, 24(2): 119-131. |
| [73] | MAIORINO M, CONRAD M, URSINI F. GPx4, lipid peroxidation, and cell death: discoveries, rediscoveries, and open issues[J]. Antioxid. Redox Signal., 2018, 29(1): 61-74. |
| [74] | AGRAWAL V, HEMNES A R, SHELBURNE N J, et al.. L-carnitine therapy improves right heart dysfunction through Cpt1-dependent fatty acid oxidation[J/OL]. Pulm. Circ., 2022, 12(3): e12107[2025-11-25]. . |
| [75] | VACANTE F, SENESI P, MONTESANO A, et al.. L-carnitine: an antioxidant remedy for the survival of cardiomyocytes under hyperglycemic condition[J/OL]. J. Diabetes Res., 2018, 2018: 4028297[2025-11-25].. |
| [76] | SCHREIBER B D. Debate forum: levocarnitine therapy is rational and justified in selected dialysis patients[J]. Blood Purif., 2006, 24(1): 128-139. |
| [77] | VESELÁ E, RACEK J, TREFIL L, et al.. Effect of L-carnitine supplementation in hemodialysis patients[J]. Nephron, 2001, 88(3): 218-223. |
| [78] | NAINI A E, SADEGHI M, MORTAZAVI M, et al.. Oral carnitine supplementation for dyslipidemia in chronic hemodialysis patients[J]. Saudi J. Kidney Dis. Transpl., 2012, 23(3): 484-488. |
| [79] | LIU Z, HUANG T, HONG Y, et al.. Adaptive antioxidant nanomedicines inhibit ferroptosis in renal tubular epithelial cells to alleviate diabetic kidney disease[J/OL]. Adv. Sci., 2025, 12(37): e05168[2025-11-25]. . |
| [1] | 梁传财, 邱波. 松果菊苷通过Nrf2/HO-1通路抑制IL-1β诱导的软骨细胞铁死亡[J]. 生物技术进展, 2025, 15(4): 720-725. |
| [2] | 丁瑜, 赵博, 张瑾, 高旭栋. SIRT1去乙酰化修饰调控HMGB1介导的细胞焦亡在慢性鼻窦炎伴鼻息肉中的作用[J]. 生物技术进展, 2025, 15(3): 535-543. |
| [3] | 王彦杰, 邱波. P53基因在骨肉瘤中的作用与研究进展[J]. 生物技术进展, 2025, 15(2): 241-246. |
| [4] | 韦双, 高维崧, 窦金萍, 赵泽鹏, 刘兴健, 李轶女. 细胞焦亡分子机制及其调控[J]. 生物技术进展, 2023, 13(6): 868-874. |
| [5] | 张明娇, 朱杰夫, 吴雄飞. 顺铂诱导的肾损伤中的细胞死亡[J]. 生物技术进展, 2023, 13(5): 718-724. |
| [6] | 王珍, 黄克让, 陈蕾, 周敏, 薛元夏. 应用高压冷冻-冷冻替代技术研究Erastin对颗粒细胞超微结构的影响[J]. 生物技术进展, 2023, 13(4): 637-644. |
| [7] | 王彦容, 郭元彪. 基于铁死亡相关LncRNA构建肝细胞癌预后模型的研究[J]. 生物技术进展, 2023, 13(3): 473-481. |
| [8] | 曹静钰, 刘承梅, 祁晨旭, 杜开颜, 陈蒙, 侯思伟. Nrf2在脊髓损伤后铁死亡的研究进展[J]. 生物技术进展, 2023, 13(2): 240-246. |
| [9] | 杜开颜, 祁晨旭, 曹静钰, 陈蒙, 高静, 刘承梅. 铁死亡参与脊髓损伤调控的研究进展[J]. 生物技术进展, 2022, 12(6): 869-874. |
| [10] | 金童, 陈铖. 铁死亡与肾脏疾病相关性的研究进展[J]. 生物技术进展, 2022, 12(1): 68-74. |
| 阅读次数 | ||||||
|
全文 |
|
|||||
|
摘要 |
|
|||||
